Researchers Urge Radiotherapy for All Patients With Bone Mets

Share this content:
Researchers Urge Radiotherapy for All Patients With Bone Mets
Researchers Urge Radiotherapy for All Patients With Bone Mets

MONDAY, Feb. 13, 2017 (HealthDay News) -- For patients with bone metastases, those responding to radiotherapy experience greater pain reduction and better quality of life (QOL) at day 10 after radiotherapy, according to a study published online Feb. 9 in JAMA Oncology.

Rachel McDonald, M.D., from Sunnybrook Health Sciences Centre in Toronto, and colleagues used a bone metastases-specific QOL tool to examine QOL at days 10 and 42 after radiotherapy among 298 patients from 23 Canadian centers.

The researchers found that 40.9 and 38.9 percent of patients responded to radiotherapy at day 10 and 42, respectively. Compared with non-responders, patients with a pain response had a greater reduction in pain (mean reduction, 17.0 versus 1.8; P = 0.002) and pain characteristics (mean reduction, 12.8 versus 1.1; P = 0.002) at day 10; they also had greater improvements in functional interference (mean increase, 11.6 versus 3.6; P = 0.01) and psychosocial aspects (mean, 1.2-point increase in responders versus 2.2-point decrease in non-responders; P = 0.04). Compared with non-responders, responders had significantly greater improvements in physical, emotional, and global domains of the European Organisation for Research and Treatment of Cancer Quality of Life Core 15 Palliative when comparing changes in QOL from baseline to day 42 (all P < 0.001).

"A single 8-Gy radiotherapy dose for bone metastases should be offered to all patients, even those with poor survival," the authors write.

Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions

More in Home

FDA Approves Bavencio for Merkel Cell Carcinoma

FDA Approves Bavencio for Merkel Cell Carcinoma

Drug targets the PD-1/PD-L1 pathway; first sanctioned treatment in the United States

Heterogeneous Association for Alcohol, CVD Presentation

Heterogeneous Association for Alcohol, CVD Presentation

Non-drinking linked to increased risks of unstable angina, MI, heart failure, ischemic stroke, PAD, AAA

Mobile App Cuts In-Person Visits After Breast Reconstruction

Mobile App Cuts In-Person Visits After Breast Reconstruction

Number of visits down, increase in e-mails to doctors for ambulatory patients undergoing breast recon

is free, fast, and customized just for you!

Already a member?

Sign In Now »